Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | MTNR1A | P48039 | 4/20 | 0.49 |
| ▸ | MTNR1B | P49286 | 4/20 | 0.49 |
| ▸ | AKR1C3 | P42330 | 4/20 | 0.47 |
| ▸ | AKR1C2 | P52895 | 4/20 | 0.47 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.47 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.47 |
| ▸ | FFAR1 | O14842 | 5/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2322439 | 1.00 | L3MBTL1 (0.50) | L3MBTL1MTNR1AMTNR1BAKR1C3AKR1C2 | |
| SCHEMBL2176161 | 1.00 | L3MBTL1 (0.50) | L3MBTL1MTNR1AMTNR1BAKR1C3AKR1C2 | |
| SCHEMBL2178238 | 1.00 | L3MBTL1 (0.50) | L3MBTL1MTNR1AMTNR1BAKR1C3AKR1C2 | |
| SCHEMBL30786879 | 1.00 | L3MBTL1 (0.50) | L3MBTL1MTNR1AMTNR1BAKR1C3AKR1C2 | |
| SCHEMBL13730285 | 0.92 | L3MBTL1 (0.47) | L3MBTL1MTNR1AMTNR1BPTGS1FFAR1 | |
| SCHEMBL2180325 | 0.87 | L3MBTL1 (0.49) | L3MBTL1MTNR1AMTNR1B | |
| SCHEMBL2154692 | 0.87 | L3MBTL1 (0.49) | L3MBTL1MTNR1AMTNR1B | |
| SCHEMBL2180203 | 0.87 | L3MBTL1 (0.49) | L3MBTL1MTNR1AMTNR1B | |
| SCHEMBL2154689 | 0.87 | L3MBTL1 (0.49) | L3MBTL1MTNR1AMTNR1B | |
| SCHEMBL13731760 | 0.87 | L3MBTL1 (0.56) | L3MBTL1MTNR1AMTNR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160102047-A1 | SUBSTITUTED N-PENTANAMIDE COMPOUNDS, PREPARATION METHOD AND THE USE THEREOF | TOPHARMAN SHANGHAI CO., LTD. (CN) | 2016-04-14 | — | — | US | disclosed |
| US-9249084-B2 | Substituted n-pentanamide compounds, preparation method and the use thereof | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2016-02-02 | — | — | US | disclosed |
| US-20140046074-A1 | Substituted n-pentanamide compounds, preparation method and the use thereof | TOPHARMAN SHANGHAI CO., LTD. (CN) | 2014-02-13 | — | — | US | disclosed |
| CN-102477016-A | Synthesis and application of intermediate of tapentadol | INST MATERIA MEDICA CAMS | 2012-05-30 | — | — | CN | disclosed |
| WO-2011092719-A2 | PROCESS FOR THE PREPARATION OF L-PHENYL-3-DIMETHYLAMINOPROPANE DERIVATIVES | IND-SWIFT LABORATORIES LIMITED (IN) | 2011-08-04 | — | — | WO | disclosed |
| WO-2011080756-A1 | PROCESS FOR THE PREPARATION OF 1-PHENYL-3-DIMETHYLAMINOPROPANE DERIVATIVES | IND-SWIFT LABORATORIES LIMITED (IN) | 2011-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160102047-A1 | SUBSTITUTED N-PENTANAMIDE COMPOUNDS, PREPARATION METHOD AND THE USE THEREOF | PNMT, TPMT, HTR3A | L3MBTL1 4615/4885MTNR1A 256/4885MTNR1B 160/4885 |
| US-20140046074-A1 | Substituted n-pentanamide compounds, preparation method and the use thereof | PNMT, TPMT, HTR3A | L3MBTL1 4583/4885MTNR1A 249/4885MTNR1B 149/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.